Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: A prospective validation by RTOG 9704

Journal of Clinical Oncology

Volumn 26, Issue 36, 2008, Pages 5918-5922

  Berger, Adam C ^a   Garcia Jr , Miguel ^a   Hoffman, John P ^a   Regine, William F ^a   Abrams, Ross A ^a   Safran, Howard ^a   Konski, Andre ^a   Benson III, Alan B ^a   MacDonald, John ^a   Willett, Christopher G ^a  

^a UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; FLUOROURACIL; GEMCITABINE;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BLOOD GROUP LEWIS SYSTEM; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PRIORITY JOURNAL; RISK REDUCTION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CA-19-9 ANTIGEN; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LEWIS BLOOD-GROUP SYSTEM; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; RADIOTHERAPY, ADJUVANT; TUMOR MARKERS, BIOLOGICAL;

EID: 58049202340     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.18.6288     Document Type: Article

References (18)

1. Jemal A, Siegel R, Ward E: Cancer Statistics, 2007. CA Cancer J Clin 57:43-66, 2007
2. Kalser MH, Ellenberg SS: Pancreatic cancer: Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 120:899-903, 1985
3. Klinkenbijl JH, Jeekel J, Sahmoud T, et al: Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 230:776-782, 1999
4. Neoptolemos JP, Dunn JA, Stocken DD, et al: Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: A randomised controlled trial. Lancet 358:1576-1585, 2001
5. Oettle H, Post S, Neuhaus P, et al: Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial. JAMA 297:267-277, 2007
6. Tempero MA, Uchida E, Takasaki H, et al: Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res 47:5501-5503, 1987
7. Montgomery RC, Hoffman JP, Riley LB, et al: Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas. Ann Surg Oncol 4:551-556, 1997
8. Regine WF, Winter KA, Abrams RA, et al: Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: A randomized controlled trial. JAMA 299:1019-1026, 2008
9. Cox, DR: Regression models and life-tables. Journal of the Royal Statistical Society, Series B 34:187-202, 1972
10. Kaplan EL, Meier P: Nonparameteric estimation from incomplete observations. J Amer Statist Assoc 53:457-481, 1958
11. Koprowski H, Steplewski Z, Mitchell K, et al: Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet 5:957-971, 1979
12. Magnani JL, Nilsson B, Brockhaus M, et al: A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentaose II. J Biol Chem 257:14365-14369, 1982
13. Lamerz R: Role of tumour markers, cytogenetics. Ann Oncol 10:145-149, 1999 (suppl 4)
14. Berger AC, Meszoely IM, Ross EA, et al: Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma. Ann Surg Oncol 11:644-649, 2004
15. Beretta E, Malesci A, Zerbi A, et al: Serum CA 19-9 in the postsurgical follow-up of patients with pancreatic cancer. Cancer 60:2428-2431, 1987
16. Glenn J, Steinberg WM, Kurtzman SH, et al: Evaluation of the utility of a radioimmunoassay for serum CA 19-9 levels in patients before and after treatment of carcinoma of the pancreas. J Clin Oncol 6:462-468, 1988
17. Ferrone CR, Finkelstein DM, Thayer SP, et al: Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol 24:2897-2902, 2006
18. Lundin J, Roberts PJ, Kuusela P, et al: Prognostic significance of serum CA 242 in pancreatic cancer: A comparison with CA 19-9. Anticancer Res 15:2181-2186, 1995